Dose-related efficacy of irbesartan for hypertension: An integrated analysis

Hypertension

Volumn 31, Issue 6, 1998, Pages 1311-1316

  Reeves, Richard A ^a   Lin, Chen Sheng ^a   Kassler Taub, Kenneth ^a   Pouleur, Hubert ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Close response; Irbesartan; Placebo; Randomized controlled trials

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; IRBESARTAN; PLACEBO;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0031864853     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.31.6.1311     Document Type: Article

References (18)

1. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1993;265:826-834.
2. Necciari J, Denolle T, Le Coz F, Donazollo Y, Pastor G, Sissmann J. Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man. J Hypertens. 1994;12:88. Abstract.
3. Ribstein J, Sissmann J, Picard A, Bouroudian M, Mimran A. Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens. 1994;12:131. Abstract.
4. Timmermans PBMWM, Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J. 1994; 15(suppl D):79-87.
5. Sissmann J, Bouroudian M, Armagnac C, Donazollo Y, Latreille M, Panis R. Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295). J Hypertens. 1994;12:S92. Abstract.
6. Pool JL, Guthrie RM, Littlejohn TW III, Raskin P, Shepherd A, Weber MA, Weir MR, Wilson TW, Wright J, Kassler-Taub KB, Reeves RA. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1998. In press.
7. Guthrie R, Saini R, Herman T, Pleskow W, Sprecher D, Collins G. Efficacy and safety of irbesartan, the angiotensin II receptor antagonist, in essential hypertension. Clin Drug Invest. 1998;15:217-227.
8. Fogari R, Ambrosoli S, Corradi L, Degli Esposti E, Mos L, Nami R, Nicrosini F, Pessina AC, Salvetti A, Vaccarella A, Zanchetti A, Martin A, Reeves RA. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens. 1997;15:1511-1518.
9. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens. 1998. In press.
10. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol. 1995;48:23-40.
11. Swales JD. Meta-analysis as a guide to clinical practice. J Hypertens. 1993;11(suppl 5):S59-S63.
12. Johnston GD. Dose-response relationships with antihypertensive drags. Pharmacol Ther. 1992;55:53-93.
13. Simon TA, Gelarden RT, Freitag SA, Kassler-Taub KB, Davies R. The safety of irbesartan in the treatment of mild-to-moderate hypertension: results of nine randomized, double-blind, placebo-controlled studies. Am J Cardiol. 1998. In press.
14. Lalonde RL. Pharmacokinetic-pharmacodynamic relationships of cardiovascular drugs. In: Derendorf H, Hochhaus G, eds. Handbook of Pharmacokinetic/Pharmacodynamic Correlation. Boca Raton, Fla: CRC Press; 1995:197-225.
15. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
16. Hagmann M, Bumier M, Nussberger J, Leenhardt AF, Brouard R, Waeber B, Brunner HR. Natriuretic and hormonal effects of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in normotensive volunteers. Am J Hypertens. 1994;7:13A. Abstract.
17. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA, Pulchalski J, Nichola P, Gelarden RT. Irbesartan in combination with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1997;10(4 pt 2):106A. Abstract.
18. Weber M, Saini R, Kassler-Taub K, Reggi D, Ferdousi T, Nalence A. Irbesartan combined with low-dose hydrochlorothiazide for mild-to-moderate hypertension. J Hypertens. 1998. In press. Abstract.